Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2026-06-18 08:37:48 ET · period of report 2026-06-16 · accession 0001104659-26-075456 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-18 08:37 | 2026-06-16 | LGND | Sabba Stephen L | Dir | M - OptEx | $66.13 | +2,145 | 35.8K | +6% | +$141.8K |
| D | 2026-06-18 08:37 | 2026-06-16 | LGND | Sabba Stephen L | Dir | S - Sale+OE | $254.00 | -2,145 | 33.6K | -6% | -$544.8K |
| D | 2026-06-18 08:37 | 2026-06-16 | LGND | Sabba Stephen L | Dir | M - OptEx | $0.00 | -2,145 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-16 | M | A | 2,145 | $66.13 | 35,774 | D | — | — | (F1) These securities, as represented in Column 5, include the grant of 836 restricted shares approved by the Board of Directors of the Company at the 2026 Meeting held 5 June 2026, which shares were previously reported on a Form 4 for this Reporting Person dated 9 June 2026. |
| 2 | Common | Common Stock | 2026-06-16 | S | D | 2,145 | $254.00 | 33,629 | D | — | — | (F1) These securities, as represented in Column 5, include the grant of 836 restricted shares approved by the Board of Directors of the Company at the 2026 Meeting held 5 June 2026, which shares were previously reported on a Form 4 for this Reporting Person dated 9 June 2026. |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-06-16 | M | D | 2,145 | $0.00 | 0 | D | $66.13 · — to 2027-05-25 | 2,145 Common Stock | (F2) These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting, as previously reported on the Reporting Person's Form 4, dated 30 May 2017. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,145 shares and the exercise price adjusted to $66.13 pursuant to the OmniAb Inc. separation from the Company. (F2) These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting, as previously reported on the Reporting Person's Form 4, dated 30 May 2017. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,145 shares and the exercise price adjusted to $66.13 pursuant to the OmniAb Inc. separation from the Company. |